About Careers MedBlog Contact us

New 'Morning After' Pill With Uterine Fibroid-Treatment Advantage

by Tanya Thomas on July 4, 2010 at 8:09 AM
Font : A-A+

 New 'Morning After' Pill With Uterine Fibroid-Treatment Advantage

A new study suggests that the experimental 'morning after' pill may be the key to freeing millions of women from the misery of uterine fibroids.

The drug, ulipristal acetate (UPA), provides an effective non-surgical treatment for the common womb condition that can lead to pain, heavy periods and infertility, say scientists.


UPA belongs to a relatively new class of drug, the selective progesterone receptor modulators or SPRMs. It is currently used for emergency contraception, and acts by blocking the progesterone receptor and hence ovulation (release of the egg).

Recent research has shown that progesterone also plays a role in the development of uterine fibroids.

"Both the fibroids and the surgical interventions commonly used to treat them can cause significant fertility problems and we wanted to see whether fibroids could shrink and surgery could be avoided by using an SPRM," Dr. Alicia Armstrong said.

In the trials, women aged from 25-50 years with symptomatic uterine fibroids were randomised to receive UPA or placebo once a day for three menstrual cycles.

The researchers found that, out of the 57 patients who it was possible to evaluate for efficacy, 18 received placebo, 20 10mg of UPA per day and 19 20mg per day. Those taking UPA had reduced total fibroid volume, with those taking the higher dose doing better - 14 (70 percent) in the 10mg group and 16 (84 percent) in the 20 mg group. The patients on placebo did significantly less well with only six (33 percent) showing reduction in fibroid volume.

UPA also reduced bleeding compared with placebo and during the third month of treatment 16 (80 percent) of patients taking 10mg daily and 18 (95 percent) on a daily dose of 20mg experienced no menstrual bleeding. At the end of the treatment, patients on the active treatment scored higher in assessment of their quality of life, the severity of their symptoms, their energy levels and mood and their overall concern about the effects of fibroids.

Estradiol levels remained adequate for bone health during treatment in 77 percent, 100 percent and 95 percent of patients in the UPA 10mg and 20mg and placebo groups, respectively, indicating that the action of the ovaries was not impaired, and neither were there any serious side effects

"The results of these trials are convincing and lead us to conclude that UPA is an effective non-invasive treatment for fibroids that can help maintain fertility in women whose only option up to now was to have surgery," Doctor Lynnette Nieman, Principal Investigator on the NIH trials said.

The study has been presented at the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome.

Source: ANI


Recommended Reading

Latest Drug News

Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
Myeloma Drug: New Findings
In myeloma (blood cancer) cells, cancer-promoting potential of the fatty acid binding proteins was found to determine to be a valid target for myeloma therapeutics
Lower Dose of Acetaminophen Linked to Reduced Serious Liver Injury
Acute liver failure cases dropped after the Food and Drug Administration rule to lower the dosage of acetaminophen
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New 'Morning After' Pill With Uterine Fibroid-Treatment Advantage Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests